Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) major shareholder Cormorant Asset Management, Lp acquired 350,000 shares of the stock in a transaction on Friday, September 20th. The shares were purchased at an average cost of $20.01 per share, with a total value of $7,003,500.00. Following the transaction, the insider now directly owns 2,375,000 shares of the company’s stock, valued at approximately $47,523,750. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Corbus Pharmaceuticals Stock Performance
Shares of CRBP traded down $0.65 on Tuesday, hitting $18.34. 1,371,666 shares of the stock traded hands, compared to its average volume of 579,737. Corbus Pharmaceuticals Holdings, Inc. has a one year low of $3.03 and a one year high of $61.90. The company has a market capitalization of $196.00 million, a PE ratio of -2.73 and a beta of 2.56. The business has a 50 day simple moving average of $54.22 and a 200 day simple moving average of $46.96.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.29. On average, equities analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -3.77 earnings per share for the current year.
Institutional Investors Weigh In On Corbus Pharmaceuticals
Analyst Ratings Changes
CRBP has been the subject of several research reports. B. Riley decreased their price target on shares of Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating for the company in a research note on Friday. Oppenheimer raised their target price on shares of Corbus Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research note on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday. Wedbush reduced their price objective on Corbus Pharmaceuticals from $85.00 to $51.00 and set an “outperform” rating for the company in a research report on Friday. Finally, StockNews.com cut Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 10th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.86.
View Our Latest Report on CRBP
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Featured Articles
- Five stocks we like better than Corbus Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- How to Choose Top Rated Stocks
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Compound Interest and Why It Matters When Investing
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.